Croce L, Romano S, Pozzoni L, Lomuscio A
Divisione di Cardiologia, Ospedale San Paolo di Milano.
Minerva Med. 1988 Mar;79(3):229-34.
Flecainide is a benzenacetamide synthesised about a decade ago and only recently introduced into the treatment of arrhythmias. Its electrophysiological properties place it in Class IC of the anti-arrhythmia drugs. Flecainide has proved useful in the treatment of supraventricular arrhythmias, atrial fibrillation (especially in patients with Wolff-Parkinson-White disease), in reciprocating supraventricular tachycardias and in focal atrial tachycardias. The drug is also extremely effective in ventricular ectopias with a success rate of over 90%. Flecainide is therefore destined to be widely used in the treatment of arrhythmias and is indicated for both supraventricular and ventricular forms, particularly those resistant to other treatment. In addition the biological availability and long half life of Flecainide make it suitable for even very prolonged treatment.
氟卡尼是一种约在十年前合成的苯乙酰胺，直到最近才被用于心律失常的治疗。其电生理特性使其属于抗心律失常药物的IC类。氟卡尼已被证明对室上性心律失常、心房颤动（尤其是预激综合征患者）、折返性室上性心动过速和局灶性房性心动过速的治疗有效。该药物对室性早搏也极为有效，成功率超过90%。因此，氟卡尼注定会被广泛用于心律失常的治疗，适用于室上性和室性心律失常，尤其是那些对其他治疗有抵抗性的类型。此外，氟卡尼的生物利用度和长半衰期使其适合甚至非常长期的治疗。
